Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 19/20 | 0.59 |
| ▸ | GABRA1 | P14867 | 10/20 | 0.59 |
| ▸ | GABRG2 | P18507 | 10/20 | 0.59 |
| ▸ | GABRB3 | P28472 | 10/20 | 0.59 |
| ▸ | GABRA3 | P34903 | 10/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.59 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.59 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.59 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18973410 | 0.91 | GABRA5 (0.48) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL18973308 | 0.91 | GABRA5 (0.58) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL26188048 | 0.91 | GABRA5 (0.48) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL18973263 | 0.91 | GABRA5 (0.58) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL20530719 | 0.90 | GABRA5 (0.65) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL24179842 | 0.87 | GABRA5 (0.49) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL21362677 | 0.87 | GABRA5 (0.61) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL18973411 | 0.87 | GABRA5 (0.44) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL21362678 | 0.86 | GABRA1 (0.67) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL18973258 | 0.86 | GABRA5 (0.60) | GABRA5GABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388433-B1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMR BIOTECH CO LTD (CN) | 2023-08-30 | — | — | EP | claimed |
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | SHANGHAI SIMR BIOTECH CO., LTD. (CN) | 2022-01-11 | — | — | US | claimed |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | SHANGHAI SIMRD BIOTECHNOLOGY. CO., LTD. (CN) | 2020-05-28 | — | — | US | claimed |
| EP-3388433-A1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotech Co., Ltd (CN) | 2018-10-17 | — | — | EP | claimed |
| EP-3388433-B1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMR BIOTECH CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | SHANGHAI SIMR BIOTECH CO., LTD. (CN) | 2022-01-11 | — | — | US | disclosed |
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | SHANGHAI SIMR BIOTECH CO., LTD. (CN) | 2022-01-11 | — | — | US | disclosed |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | SHANGHAI SIMRD BIOTECHNOLOGY. CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | SHANGHAI SIMRD BIOTECHNOLOGY. CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3388433-A1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotech Co., Ltd (CN) | 2018-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | GABRA5, CYP3A5, GABRA1 | GABRA5 1/4885GABRA1 3/4885GABRG2 23/4885 |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | GABRA5, CYP3A5, GABRA1 | GABRA5 1/4885GABRA1 3/4885GABRG2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.